JOHNSON & JOHNSON 853260 - wohl das am konstantesten wachsende Unternehmen der Welt (Seite 58)

[spaceistheplace]

hört sich nicht so doll an:

Amgen, J&J Anemia Drugs Have Blood Clot, Death Risk - Study2-26-08 4:15 PM EST | E-mail Article | Print Article

WASHINGTON -(Dow Jones)- An analysis of about 50 studies involving Amgen Inc.'s (AMGN) and Johnson & Johnson (JNJ)'s anti-anemia drugs suggests the products are associated with an increased risk of death and blood clots.
The analysis, which is being published in this week's Journal of the American Medical Association, looked at 51 Phase III clinical studies involving Aranesp, Epogen and Procrit in patients with cancer and comes amid an ongoing safety review of the drugs by the U.S. Food and Drug Administration. Phase III studies are advanced clinical studies that are typically conducted to support FDA approval of products.

Previous studies have suggested the drugs increase the risk of blood clots and the drugs' labels already warn of that risk, while certain individual studies of the drugs in cancer patients have suggested the drugs might shorten overall survival.

Twice last year, the FDA updated the drugs' labels to warn of safety problems and the agency will be convening its outside advisory panel of cancer experts on March 13 to discuss two additional studies involving cancer patients that have come out since November. The agency has said it "may take" additional regulatory action involving the drugs but, for now, it has advised patients and doctors to discuss the benefits and risks of the products before deciding whether to use them.

The analysis, led by Charles L. Bennett, an oncologist and medical professor at Northwestern University, looked at 51 clinical trials with 13,611 patients to examine survival. Overall, the analysis showed patients being treated with the drugs had about a 10% higher risk of dying than patients not receiving the drugs, a finding Bennett said was "statistically significant." The risk of venous thromboembolism, or blood clots, was looked at in 38 studies that included 8,172 patients. Overall, those studies found an increased blood-clot risk of 57% among patients receiving the anti-anemia drugs.

"These risks have been previously defined," said Roger Perlmutter, Amgen's executive vice president of research and development. "There are benefits associated with use of these drugs and there are risks."

Amgen makes all three anti-anemia drugs, and Procrit is marketed by Ortho Biotech, a Johnson & Johnson unit, under a license agreement with Amgen. The drugs treat anemia by boosting the number of red-blood cells and are used to treat patients with kidney disease and certain cancer patients receiving chemotherapy. The drugs have been successful at helping patients avoid blood transfusions, which are necessary to boost red-blood cell levels that fall too low. The products fall into a class of drugs known as erythropoiesis-stimulating agents, or ESAs.

Bennett said more research is needed to look at the drugs' impact on tumors, noting that some studies have shown faster tumor growth, in order to figure out which patients should or shouldn't receive treatment with the drugs. Other research has suggested that the same mechanism the drugs use to boost red-blood cell counts could also fuel tumor growth.

-By Jennifer Corbett Dooren, Dow Jones Newswires; 202-862-9294; [e-mail]

(END) Dow Jones Newswires
02-26-081615ET
Copyright (c) 2008 Dow Jones & Company, Inc.

[spaceistheplace]

schöner Artikel zu JNJ:

Johnson & Johnson: Doubling Its Dividend Every 5 Years

http://seekingalpha.com/article/65466-johnson-johnson-doubli…

[spaceistheplace]

interessant:


Johnson & Johnson Pharmaceutical Pipeline Review
posted on: February 18, 2008 | about stocks: JNJ
Print Email

Dow component Johnson & Johnson Inc. (NYSE: JNJ) recently reported 4Q07 earnings of $0.88 and FY07 EPS of $4.15, a 10% increase from 2006 and $0.02 above analysts estimates (see conference call transcript). I will take this time to provide you with an overview of the company's pharmaceutical portfolio and its outlook for FY08.

In 2007, pharmaceutical sales increased 4% overall (6% ex-US).

Existing Drugs

1) Topamax - Strong 2007 performer, approval for epilepsy treatment in 2007, boost from usage as migraine prevention, mostly US, generic competition in 2009?

2) Levaquin - Strong 2007 performer, growth in international sales buoyed 2007 revenues, increased competition in the US

3) Risperdal (Consta and Invega) - Strong 2007 performer, but older version hurt by generic competition in international markets, patent being challenged by generics in US.

4) Remicade - Strong 2007 performer, increased competition
from other biologics, strong international growth

5) Aciphex - Strong 2007 performer, patent being challenged by generics

6) Concerta - Strong 2007 performer, possible generic in the wings as JNJ asks FDA for clinical trials

7) Velcade - Strong 2007 performer, pending EU approval for use on multiple myeloma

8) Eprex/Procrit - 12% decline in revenue, safety concerns, competition (Amgen/Aranesp), competition in Europe (Roche/Mircera), Medicare restrictions

9) Duragesic - generic competition started in 2007

10) Ultracet - generic competition started in 2007

11) Sporanox - generic competition started in 2007

12) Ortho Tri-Cyclen - huge competition for oral contraceptives, patent being challenged by generics

13) Razadyne - patent being challenged by generics

Drug Pipeline

1) Doribax - approved in October 2007 for UTIs, pending for pneumonia, and on all accounts in EU

2) Intelence - HIV/AIDS drug approved this month

3) A schizophrenia drug coming online possible Fall 2008

4) Depoxetene in Europe for premature ejaculation, possible 2008 market date

5) Cefpobritole for complicated skin infections and pneumonia, possible 2008 market date

6) A drug for plaque psoriasis, possible 2008 market date

7) Tapentadol filing for approval in 2008

8) Rivaroxaban for knee and hip replacement patients filing in 2008

9) A drug to treat RA , filing for approval in 2008

10) Telaprevir for hep C, filing for approval in 2010

11) An oral factor Xa inhibitor strong Phase III results

Feel free to post updates or corrections.

[spaceistheplace]

04.02.2008 14:22
FDA to review J&J psoriasis drug
Private Equity boomt!
16% p.a. seit 50 Jahren! 7% Sofortrente! Hohe Renditen bei breiter Risikostreuung!
Top Steuersparmodell
Steuern sparen mit Denkmal Immobilien: Bis zu 90% des Kaufpreises abschreibbar!
Welcher Typ sind Sie?
Für jeden Anlage-Typ das passende Produkt von AKZENT Invest. Machen auch Sie mehr aus Ihrem Geld.

HORSHAM, Pa. (AP) - Johnson&Johnson's subsidiary Centocor Inc. said Monday the Food and Drug Administration will review its application for experimental drug CNTO 1275 for the treatment of psoriasis, a skin disease.

Centocor is seeking approval for the late-stage drug, also known as ustekinumab, to treat adults with chronic moderate-to-severe plaque psoriasis, which results from the overproduction of skin cells and causes red, scaly plaques that itch and bleed.

Centocor discovered ustekinumab and holds exclusive marketing rights to the product in the United States. Janssen-Cilag International NV has exclusive marketing rights in countries outside of the United States.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

[spaceistheplace]

der Vollständigkeite halber:


J&J 4Q Profit Rises; Revenue Climbs
By LINDA A. JOHNSON
Font Scale:
Posted 22 January 2008 @ 01:07 pm EST

* IBTimes RSS
* Print
* E-Mail
* digg
* Del.icio.us

TRENTON, N.J. (AP) - Health care products maker Johnson & Johnson's profit rose almost 10 percent in the fourth quarter as revenues jumped by double digits despite sales drops for two key product lines.

Article Tags
4q climbs profit revenue rises

* Merrill Takes $11.5 Bln Write-Down
* IBM's Strong 4Q Results Boost Tech Sector
* Bank of America 4Q Profit Plunges

More News Related to 4q >>

* Meredith 2Q Profit Climbs on Publishing
* Dollar Climbs Against Euro
* Ark. Unemployment Rate Climbs

More News Related to climbs >>

* Coca-Cola Enterprises boosts 2007 profit estimate
* Cisco Eanings Jump, Shares Slide on Outlook
* Expedia third-quarter profit gains on bookings

More News Related to profit >>

* GE Profit Meets Expectations
* Wesfarmers-Coles combined revenue seen at $39 bln

More News Related to revenue >>

* Oil rises on weaker dollar, OPEC
* Frontier Airlines traffic rises 22Pct.
* Berkshire Profit Rises 64pct

More News Related to rises >>

The New Brunswick, N.J.-based maker of prescription drugs, medical devices, contact lenses and baby care items on Tuesday reported net income of $2.37 billion, or 82 cents per share, up from $2.17 billion, or 74 cents per share, a year earlier. Excluding one-time items, net income would have been 88 cents per share.

Revenues totaled $15.96 billion, up 16.6 percent from $13.7 billion in the year-ago quarter. Most growth came overseas, with international sales jumping 26 percent and currency exchange rates boosting revenues nearly 5 percent.

"This is as good as it gets for them, and it is not a harbinger for good times in the future," said analyst Steve Brozak of WBB Securities.

Analysts surveyed by Thomson Financial were expecting earnings of 86 cents per share excluding one-time items on revenues of $15.4 billion.

"In 2007, we delivered strong results across our broad base of businesses and exceeded expectations," Chief Executive Officer Bill Weldon told analysts at a meeting. "We achieved those results despite having to work through one of the more difficult years in Johnson & Johnson's history."

Last July, the company announced its biggest restructuring ever, saying it would cut up to 4 percent of jobs due to looming patent expirations for key drugs and continuing sales declines for two top products. Anemia treatment Procrit J&J's No. 1 drug until 2005 saw sales fall 20 percent to $628 million in the fourth quarter. In the same quarter, sales fell nearly one-third to $415 million for Cypher, a metal-mesh tube, or stent, that slowly releases medicine to keep a heart artery open after a blockage is cleared.

Brozak said he expects Procrit sales to continue to fall and doesn't see "the stent business getting better."

In the fourth quarter, sales for J&J's medical devices and diagnostics business rose 11 percent, to $5.8 billion, while prescription drug sales rose 7.5 percent to $6.4 billion. Sales of consumer health products such skin and dental products and nonprescription medicines hit $3.8 billion, up 48 percent, mainly due to the December 2006 acquisition of Pfizer Inc.'s consumer health business.

J&J said it expects earnings per share for 2008 to total $4.39 to $4.44, excluding one-time items. Analysts have been looking for earnings of $4.42 a share for 2008.

[spaceistheplace]

20.01.2008 22:37
Johnson & Johnson says unit's HIV drug granted FDA accelerated approval

LONDON (Thomson Financial) - Johnson&Johnson (News/Aktienkurs) said the US Food and Drug has granted accelerated approval to the anti-HIV medication Intelence tablets, developed by Johnson&Johnson unit Tibotec, a division of Ortho Biotech Products LP.

The drug is used as part of HIV combination therapy, Johnson&Johnson said.

FDA accelerated approval procedures allow for earlier approval of drugs

that provide a meaningful therapeutic benefit over existing treatment for

serious or life-threatening diseases.

[e-mail]

vs

[spaceistheplace]

10.01.2008 19:37
FDA sets February meeting for J&J drug

WASHINGTON (AP) - Government advisers will meet in late February to review Johnson&Johnson's antibiotic to treat skin infections.

The Food and Drug Administration's panel of outside antibiotic experts will consider approval of the company's ceftobiprole at a Feb. 28 meeting, according to a notice posted to the agency's Web site. The FDA is not required to follow the panel's recommendations, though it often does.

Shares of Johnson&Johnson (News/Aktienkurs) were flat at $67.8o in afternoon trading.

Copyright 2007 Associated Press. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

[spaceistheplace]

ganz nett:

http://www.reuters.com/article/businessNews/idUSN07411135200…

[spaceistheplace]

Guten Morgen zusammen,

hier mal geschwind ne Analomeinung, die aber genau das sagt, was wir schon lange wissen. JNJ ist ein Feld in der Brandung.

Gruss space

04.01.2008 20:35
Johnson & Johnson: Sicherer Hafen - sagt die UBS
New Brunswick, New Jersey (BoerseGo.de) - Der Pharmariese Johnson&Johnson (News/Aktienkurs) ist einer den wenigen, die sich dem Abwärtssog entziehen können. Dazu trägt die UBS (News/Aktienkurs) bei. Die Schweizer starten die Beobachtung mit „Kaufen“ und Kursziel 77 Dollar. Als einer der am breitesten diversifizierten US-Gesundheitskonzerne sei der Pillenhersteller ein „sicherer Hafen“ heißt es dort. Zwar rechne die UBS mit fallenden Umsätzen in diesem und im kommenden Jahr, weil wichtige Patente auslaufen, aber ab 2009 sollte die vielversprechende Pipeline an neuen Präparaten wieder für Wachstum sorgen.

Der Dow-Titel gewinnt 0,55% auf 66,29 Dollar.

[Pontiuspilatus]

wobei dem volk als notwendigkeit steigender staatseinnahmen immer soziale gerechtigkeit als totschlagargument präsentiert wird.
de facto kann der staat dieses ziel falls es überhaupt ein sinnvolles ziel sein sollte ( ich denke eher es ist eher eine manie welche ohne groß darüber nachzudenken allgemein akzeptiert ist so das man wenn man dies ablehnt als irrer angesehen wir) nicht erreichen.

es ist sogar so das trotz zunehmender bürokratisierung, steigender steuer und abgeabenlasten usw. usw. die sozialen unterschiede immer mehr zunehmen.

daraus lässt sich gut erkenne das steigende staatseinnahmen in keinem kausalen zusammenhang mit sozialer gerechtigkeit stehen.

die dem volk vom staatsaparat aufgebürdeten kosten haben eher den zweck die aufgeblähten und verfilzten korrupten strukturen in sozialkassen und politik zu finanzieren.

d.h das volk finanziert diejenigen welche seine handlungsfreiheit immer mehr einschränken und dies damt begründen das man nur das beste für das volk will.

Wie gesagt die menschensind dumm